Association between previous use of antiplatelet therapy and intracerebral hemorrhage outcomes Khan NI, Siddiqui FM, Goldstein JN, et al. Stroke 2017; 48:1810-1817. Abstract BACKGROUND: Although the use of antiplatelet therapy (APT) is associated with the risk of intracerebral hemorrhage (ICH), there are limited data on prestroke APT and outcomes, particularly among patients on combination APT […]
The Neurology Lounge strives hard to keep to the straight and narrow path of clinical neurology. But every now and then it takes a peek at what is happening at the cutting edge of neuroscience. And what can be more cutting edge then biomarkers, with their promise of simplifying disease identification, making prompt and accurate diagnosis an effortless task.
The quintessential biomarker however remains as elusive as quicksilver. Not that one could tell, going by the rate biomarkers are being spun from the neuroscience mills. Biomarkers are the buzz in many neurological fields, from brain tumours to multiple sclerosis (MS), from Alzheimer’s disease (AD) to Huntington’s disease (HD).
The proliferation of contending biomarkers is however probably highest in the field of motor neurone disease (MND). Is there a holy grail out there to enable the rapid and accurate diagnosis of this relentlessly progressive disease? There is clearly no dearth of substances jostling for prime position in the promised land of MND biomarkers. Below is a shortlist of potential MND CSF biomarkers; just click on any to go to the source!
Biomarkers elevated in the cerebrospinal fluid (CSF)
Biomarkers reduced in the cerebrospinal fluid (CSF)
Why not check out more about MND in Neurochecklists
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. Rolnik DL, Wright D, Poon LC, et al. N Engl J Med 2017; 377:613-622. Abstract BACKGROUND: Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. METHODS: In this multicenter, double-blind, placebo-controlled trial, we […]
Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy Geller EB, Skarpaas TL, Gross RE, et al. Epilepsia 2017; 58:994-1004. Abstract OBJECTIVE: Evaluate the seizure-reduction response and safety of mesial temporal lobe (MTL) brain-responsive stimulation in adults with medically intractable partial-onset seizures of mesial temporal lobe origin. METHODS: Subjects with mesial temporal lobe […]